Home Cart Sign in  
Chemical Structure| 49671-76-3 Chemical Structure| 49671-76-3

Structure of ZLN005
CAS No.: 49671-76-3

Chemical Structure| 49671-76-3

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

ZLN005 stands out as a highly potent activator of peroxisome proliferator-activated receptor-γ coactivator-1α (PGC-1α).

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of ZLN005

CAS No. :49671-76-3
Formula : C17H18N2
M.W : 250.34
SMILES Code : CC(C1=CC=C(C2=NC3=CC=CC=C3N2)C=C1)(C)C
MDL No. :MFCD01560221
InChI Key :LQUNNCQSFFKSSK-UHFFFAOYSA-N
Pubchem ID :899323

Safety of ZLN005

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H319-H413
Precautionary Statements:P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
L6 myotubes 10-20 μmol/L 24 hours ZLN005 increased PGC-1α mRNA levels, improved glucose uptake, and fatty acid oxidation. PMC3609556
rat primary hepatocytes 10-20 μmol/L 24 hours ZLN005 had no significant effect on PGC-1α mRNA levels in rat primary hepatocytes. PMC3609556

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
db/db mice diabetic model oral 30 mg/kg body weight once daily for 8 days ZLN005 increased PGC-1α and downstream gene transcription in skeletal muscle, reduced hepatic PGC-1α and gluconeogenesis genes, and improved glucose tolerance, pyruvate tolerance, and insulin sensitivity in db/db mice. PMC3609556
C57BL/6J mice Doxorubicin-induced cardiomyopathy model Intravenous injection 750 mg/kg single injection, up to 42 days ZLN005 significantly mitigated the doxorubicin-induced cardiomyopathy phenotype, improved myocardial mass, reduced heart dilatation and vacuolations, and enhanced overall structural integrity. PMC10525725

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

3.99mL

0.80mL

0.40mL

19.97mL

3.99mL

2.00mL

39.95mL

7.99mL

3.99mL

References

 

Historical Records

Categories